Discure Technologies Accepted into FDA TAP Program for Its Breakthrough Device for Degenerative Disc Disease
FDA’s Total Product Life Cycle (TPLC) Advisory Program acceptance will accelerate development and market access for its bioelectronic therapy for leading cause of low back pain
PETACH-TIKVA, Israel, March 04, 2025 (GLOBE NEWSWIRE) — Discure Technologies, a clinical-stage medical device company pioneering treatments for degenerative disc disease and other orthopedic disorders, today announced its acceptance into the U.S. Food and Drug Administration’s (FDA) Total Product Life Cycle (TPLC) Advisory Program (TAP). Acceptance to TAP will expedite patient access to Discure’s bioelectronic implant, the Discure System, which previously received Breakthrough Device designation from the FDA.
